{"id":"W4379232529","doi":"10.3390/curroncol30060411","title":"HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of British Columbia; Dr. H. Bliss Murphy Cancer Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Mount Sinai Hospital","funders":"Novartis Pharmaceuticals Canada; Astellas Pharma; Mylan; Genomic Health; Seagen; Gilead Sciences; Sanofi; Amgen; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Palbociclib; Fulvestrant; Oncology; Internal medicine; Breast cancer; Cancer; Disease; Metastatic breast cancer; Bevacizumab; Life expectancy; Intensive care medicine; Tamoxifen; Population; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001726492,0.0007068979,0.001362731,0.001833407,0.0002900237,0.001424179,0.001250804,0.00128982,0.007451098],"category_scores_gemma":[0.006358182,0.0002415833,0.001757042,0.001753996,0.0002677249,0.001144628,0.0005842308,0.001337711,0.001270662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00114663,"about_ca_system_score_gemma":0.003519607,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0034082,"about_ca_topic_score_gemma":0.009128238,"domain_scores_codex":[0.9991935,0.0002405137,0.0001863072,0.0000928966,0.0002281697,0.00005854134],"domain_scores_gemma":[0.996682,0.001999754,0.000503192,0.00003894295,0.0006910364,0.000085098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001197874,0.00004608698,0.0002849874,0.1230219,0.0005435375,0.0002181785,0.0001389067,0.0006052544,0.0003865001,0.001996845,0.09430762,0.7783304],"study_design_scores_gemma":[0.00007924485,0.0001159295,0.001131788,0.1676771,0.001855858,0.001125787,0.0001262513,0.0002134684,0.0002281554,0.001742864,0.8256673,0.00003615566],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001263041,0.9959883,0.0001838862,0.001636284,0.0003521396,0.00002532283,0.0001047088,0.00001018012,0.001572945],"genre_scores_gemma":[0.001227428,0.9966185,0.0004064754,0.001048055,0.0002339257,0.00002688908,0.0001084585,0.000003251521,0.000327028],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007451098,"threshold_uncertainty_score":0.02492636,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2135830166260177,"score_gpt":0.5293600720080169,"score_spread":0.3157770553819992,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}